Mindray to Acquire a Controlling Stake in TDR Biotech
Under the agreement, TDR will give Mindray access to its microbiology analysis products as well as its R&D, manufacture, sales and services capabilities. TDR’s platform for microbiology analysis business will be a great supplementary to our existing in-vitro diagnostic product line.
Mindray will use its strong platforms in sales, manufacture, R&D, quality assurance and human resources to support TDR’s future development. Mindray aims to work diligently with TDR to help the company become a leader in the promising microbiology analysis business in China.
We believe the collaboration between Mindray and TDR will bring many synergies to both parties. Together, we will provide better products and services to our customers, and broader development opportunities to our employees. Mindray will also help strengthen TDR’s position in the marketplace.
Established in 1995, Hunan Changsha Tiandiren Biotech Co. Ltd. is a high-tech enterprise headquartered in Changsha, engaged in microbiological diagnostic analyzer and ancillary reagents. Please refer to www.tdr-hn.com for more information.
Open WeChat and Scan the QR code .Get the Webpage and Share on Moments.
Mindray becomes the first China medical device manufacturer that received MDR certificate2019-11-22
Mindray Showcases Comprehensive Innovations at MEDICA 20192019-11-20
Mindray launches the new BeneHeart C Series AED to enhance resuscitation confidence2019-09-12
Mindray Showcases Latest IVD Innovations at EuroMedlab 20192019-06-28
Mindray at CMEF 2019: A Journey of Global Healthcare2019-05-20